Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bavdegalutamide in mCRPC
NCT03888612Phase 2Completed
- Sponsor
- Arvinas
- Start
- Mar 2019
- Primary completion
- Apr 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bavdegalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Arvinas. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 Days, Adverse Events at 28 Days and 2 more. Started Mar 2019; status: completed.
02
Drugs
bavdegalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03888612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888612.